Efficacy of Salmeterol Xinafoate in the Treatment of COPD [PDF]
Chest, 1999 To examine and compare the efficacy and safety of salmeterol xinafoate, a long-acting inhaled beta2-adrenergic agonist, with inhaled ipratropium bromide and inhaled placebo in patients with COPD.A stratified, randomized, double-blind, double-dummy, placebo-controlled, parallel group clinical trial.Multiple sites at clinics and university medical ...
Donald A. Mahler +9 more
exaly +5 more sources
HPTLC-densitometric method for simultaneous determination of salmeterol xinafoate and fluticasone propionate in dry powder inhalers. [PDF]
Saudi Pharm J, 2010 Kasaye L, Hymete A, Mohamed AM.
europepmc +4 more sources
Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol [PDF]
BMJ Open Respiratory Research, 2023 Background Fluticasone propionate/salmeterol xinafoate (FP/SAL) is an inhaled corticosteroid (ICS) and long-acting β2-agonist (LABA) combination, indicated for the regular treatment of children (aged >4 years) with asthma that is inadequately ...
Sira Nanthapisal +4 more
doaj +2 more sources
Prevention of exercise induced asthma by inhaled salmeterol xinafoate. [PDF]
Archives of Disease in Childhood, 1992 The effect of inhaled salmeterol xinafoate, a long acting beta 2 agonist, on exercise induced asthma was studied in a double blind, crossover, and placebo controlled trial. Thirteen asthmatic children with a fall of at least 15% in their forced expiratory volume in one second (FEV1) after a standard exercise test on a motorised treadmill, on separate ...
C P Green, Jack Price
openalex +4 more sources
Novel Fluticasone Propionate and Salmeterol Fixed-Dose Combination Nano-Encapsulated Particles Using Polyamide Based on L-Lysine [PDF]
Pharmaceuticals, 2022 One of the key challenges in developing a dry powder inhaler (DPI) of an inhalable potent fixed-dose combination (FDC) is the ability of the formulation to generate an effective and reproducible aerosol able to reach the lower parts of the lungs. Herein,
Mohammad H. Alyami +5 more
doaj +2 more sources
The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study [PDF]
International Journal of COPD, 2017 Rupert Jones,1 Jessica Martin,2 Vicky Thomas,3 Derek Skinner,4 Jonathan Marshall,5 Martina Stagno d’Alcontres,2 David Price2,6 1Clinical Trials and Health Research, Institute of Translational and Stratified Medicine, Plymouth University Peninsula ...
Jones R +6 more
doaj +4 more sources
Allergology International, 2006 Background: The clinical efficacy of combination therapy comprising a long acting β2-agonist (LABA) and corticosteroid is widely recognized for the treatment of adult asthma.
Hirotomo Akabane +7 more
doaj +2 more sources
Effect of salmeterol xinafoate on lung mucociliary clearance in patients with asthma
Respiratory Medicine, 2003 Lung mucociliary clearance is impaired in stable asthma. The long-acting beta2-agonist salmeterol has been shown in vitro to cause a significant increase in ciliary beat frequency. It seemed possible therefore that salmeterol may also have a favourable effect on lung mucociliary transport in asthmatic patients.
A Hasani +4 more
openalex +3 more sources
Preclinical evaluation of novel synthesised nanoparticles based on tyrosine poly(ester amide) for improved targeted pulmonary delivery [PDF]
Scientific ReportsFixed dose combinations (FDCs) incorporating two or three medicines in a single inhaler have been created to enhance patient compliance and hence clinical outcomes.
Eman Zmaily Dahmash +6 more
doaj +2 more sources
METHOD DEVELOPMENT AND VALIDATION OF THE CHROMATOGRAPHIC ANALYSIS OF FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE COMBINATION IN SOLUTIONS AND HUMAN PLASMA USING HPLC WITH UV DETECTION [PDF]
, 2021 Objective: A simple, Rapid, and sensitive HPLC method utilizing UV detection was developed and validated for the simultaneous estimation of Fluticasone propionate (FP) and Salmeterol xinafoate (SX) in solutions and in vitro human plasma.
A. SHAMMOUT, MOHAMMAD JAMAL +6 more
core +4 more sources